Pinmai Khosit, Chunlaratthanabhorn Sriharut, Ngamkitidechakul Chatri, Soonthornchareon Noppamas, Hahnvajanawong Chariya
Department of Preclinical Science, Faculty of Medicine, Thammasat University, Paholyotin Rd., Amphur Klongluang, Pathumthani 12120, Thailand.
World J Gastroenterol. 2008 Mar 14;14(10):1491-7. doi: 10.3748/wjg.14.1491.
To examine the growth inhibitory effects of Phyllanthus emblica (P. emblica) and Terminalia bellerica (T. bellerica) extracts on human hepatocellular carcinoma (HepG2), and lung carcinoma (A549) cells and their synergistic effect with doxorubicin or cisplatin.
HepG2 and A549 cells were treated with P. emblica and T. bellerica extracts either alone or in combination with doxorubicin or cisplatin and effects on cell growth were determined using the sulforhodamine B (SRB) assay. The isobologram and combination index (CI) method of Chou-Talalay were used to evaluate interactions between plant extracts and drugs.
P. emblica and T. bellerica extracts demonstrated growth inhibitory activity, with a certain degree of selectivity against the two cancer cell lines tested. Synergistic effects (CI < 1) for P. emblica/doxorubicin or cisplatin at different dose levels were demonstrated in A549 and HepG2 cells. The T. bellerica/cisplatin or doxorubicin also showed synergistic effects in A549 and HepG2 cells. In some instances, the combinations resulted in antagonistic effects. The dose reduction level was different and specific to each combination and cell line.
The growth inhibitory activity of doxorubicin or cisplatin, as a single agent, may be modified by combinations of P. emblica or T. bellerica extracts and be synergistically enhanced in some cases. Depending on the combination ratio, the doses for each drug for a given degree of effect in the combination may be reduced. The mechanisms involved in this interaction between chemotherapeutic drugs and plant extracts remain unclear and should be further evaluated.
研究余甘子（Phyllanthus emblica，P. emblica）和毗黎勒（Terminalia bellerica，T. bellerica）提取物对人肝癌细胞（HepG2）和肺癌细胞（A549）的生长抑制作用及其与多柔比星或顺铂的协同作用。
用余甘子和毗黎勒提取物单独或与多柔比星或顺铂联合处理HepG2和A549细胞，采用磺酰罗丹明B（SRB）法测定对细胞生长的影响。采用Chou-Talalay的等效线图和联合指数（CI）法评估植物提取物与药物之间的相互作用。
余甘子和毗黎勒提取物具有生长抑制活性，对所测试的两种癌细胞系具有一定程度的选择性。在A549和HepG2细胞中，不同剂量水平的余甘子/多柔比星或顺铂表现出协同作用（CI<1）。毗黎勒/顺铂或多柔比星在A549和HepG2细胞中也表现出协同作用。在某些情况下，联合用药产生了拮抗作用。剂量降低水平因每种联合用药和细胞系而异。
多柔比星或顺铂作为单一药物的生长抑制活性可能会因余甘子或毗黎勒提取物的联合使用而改变，在某些情况下会协同增强。根据联合比例，联合用药达到给定效应程度时每种药物的剂量可能会降低。化疗药物与植物提取物之间这种相互作用的机制尚不清楚，应进一步评估。
